Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Assets Average (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Assets Average for 15 consecutive years, with $74.2 million as the latest value for Q4 2025.

  • For Q4 2025, Assets Average fell 30.3% year-over-year to $74.2 million; the TTM value through Dec 2025 reached $74.2 million, down 30.3%, while the annual FY2025 figure was $80.7 million, 39.55% down from the prior year.
  • Assets Average hit $74.2 million in Q4 2025 for Sangamo Therapeutics, down from $93.1 million in the prior quarter.
  • Across five years, Assets Average topped out at $907.8 million in Q1 2021 and bottomed at $74.2 million in Q4 2025.
  • Average Assets Average over 5 years is $399.6 million, with a median of $327.6 million recorded in 2023.
  • Year-over-year, Assets Average skyrocketed 48.61% in 2021 and then plummeted 71.01% in 2024.
  • Sangamo Therapeutics' Assets Average stood at $747.2 million in 2021, then dropped by 22.61% to $578.2 million in 2022, then crashed by 66.71% to $192.5 million in 2023, then plummeted by 44.7% to $106.4 million in 2024, then tumbled by 30.3% to $74.2 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $74.2 million, $93.1 million, and $91.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.